Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Mike Doustdar

Mike Doustdar

President and Chief Executive Officer, Novo Nordisk

Appears in 1 story

Notable Quotes

"At a time when parts of the industry are stepping back from insulin, we are reaffirming our commitment — continuing to invest in innovation, access, and supply for the millions of patients who rely on insulin every day." — Statement on Awiqli approval, March 2026

Stories

Food and Drug Administration approves first once-weekly basal insulin

New Capabilities

Led company through Awiqli's approval

For 104 years, every insulin on the market has required at least one injection per day. On March 26, the Food and Drug Administration (FDA) approved Awiqli, a once-weekly basal insulin made by Novo Nordisk, for adults with type 2 diabetes — cutting the number of basal insulin injections from 365 to 52 per year.

Updated Yesterday